Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FDA guides on how AA can be converted to full approval.

<< Previous

Bullboard Posts

Next >>

Comment by Kswdeluxon Mar 26, 2023 4:45pm

161 Views

Post# 35361430

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA guides on how AA can be converted to full approval.

All I was getting at was a potential for a ballpark price. Google the cost of cancer patient treatment costs, and it will tell you the avergage monthly cost of cancer treatment for a patient ranges from $1000/mo to $12,000/mo. That is a seriously big range.

Products like Roche's Tecentriq was turned down overseas due to it is costly and efficacy is only 1 or 2 in 5.
So there is information out there as to the general cost of a drug treatment.

With ONC we have no current idea as to treatment costs per patient. We are told is is not costly to produce, so what is the cost of ONC treatment?

$1000/mo or $8,000/mo or $12,000/mo? Per patient? we have no idea at this time.

Healthcare will need to understand treatment budgets to understand if they can afford it.
so budgetary information becomes available to them and on an indirect path or not available to the public.

Thus an idea of cost of treatment will be out there for Healthcare to evaluate cost benefits.

I totally understand that BP keeps all that under wraps, I was not looking for lectures on corporate secrets and profit margins from Can and Note.

All I was trying to get at (thinking) is that once ONC becomes saleable, Heathcare has to evaluate and report costs of treatment somewhere, so there will be some idea somewhere of what ONC cost treatment is, as Healthcare is not an open cheque book.

Healthcare has to understand cost of treatment in order to agree to finance and pay for it.

So my question was... is treatment cost discounted in trials or not? Without writing a book of explanations...

Once a person has an understanding of a treatment cost, analysts can use what ever industry factors and formulas they want to guess at profit margins, etc. There are general formulas for all that in evaluations.

But and this was what I was getting at, there is a serious difference between a 20%-30% margin on a $1,000 treatment vs a $12,000 treatment multipled by 300,000 - 6000,000 patients a year.

So yes, having some understanding of the ball park costs of ONC treatment helps in evaluation.